Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
OtherIUPHAR Compendium of Voltage-Gated Ion Channels 2005

International Union of Pharmacology. LIV. Nomenclature and Molecular Relationships of Inwardly Rectifying Potassium Channels

Yoshihiro Kubo, John P. Adelman, David E. Clapham, Lily Y. Jan, Andreas Karschin, Yoshihisa Kurachi, Michel Lazdunski, Colin G. Nichols, Susumu Seino and Carol A. Vandenberg
Pharmacological Reviews December 2005, 57 (4) 509-526; DOI: https://doi.org/10.1124/pr.57.4.11
Yoshihiro Kubo
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John P. Adelman
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Clapham
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lily Y. Jan
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Karschin
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihisa Kurachi
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Lazdunski
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin G. Nichols
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susumu Seino
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol A. Vandenberg
Division of Biophysics and Neurobiology, Department of Molecular Physiology, National Institute for Physiological Sciences, Myodaiji, Okazaki, Aichi, Japan (Y.K.); Vollum Institute, Oregon Health Sciences University, Portland, Oregon (J.P.A.); Howard Hughes Medical Institute, Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.E.C.); Howard Hughes Medical Institute, Department of Physiology and Biochemistry, University of California, San Francisco, San Francisco, California (L.Y.J.); Institute of Physiology, University of Würzburg, Würzburg, Germany (A.K.); Department of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (Y.K.); Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Propre de Recherche 411,Valbonne, France (M.L.); Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (C.G.N.); Division of Cellular and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Hyago, Japan (S.S.); and Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California (C.A.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Introduction

Since the initial cDNA cloning of the first inward rectifiers Kir1.1 (ROMK1) and Kir2.1 (IRK1) in 1993, a succession of new members of this family have been identified, including the G protein-coupled Kir3 and the ATP-sensitive Kir6. These channels play an important physiological role in the function of many organs, including brain, heart, kidney, endocrine cells, ears, and retina. The phylogenic tree shown in Fig. 1 illustrates the relationships between the seven Kir subfamilies based on amino acid sequence alignments. No new members of this family have been identified since this tree appeared in the 2002 edition of The IUPHAR Compendium of Voltage-Gated Ion Channels, and it is unlikely that any other members remain to be discovered.

In the Kir section of the 2002 edition, we cited a very limited number of original cDNA cloning papers (Kubo et al., 2002). The scope of these citations has been expanded herein so that inferences on the molecular architecture and functional and pharmacological aspects can be readily drawn. Some of the newer work cited in this article is outlined below. It is noteworthy that much of this work describes the identification of associating proteins and the link between particular Kir genes and human diseases. These kinds of findings are expected to continue to increase:

  1. The interaction of Kir1.1 with Na+/H+ exchange regulatory factor 2 in the postsynaptic density 95/disc-large/zona occludens (PDZ) complex was reported (Yoo et al., 2004).

  2. The assembly of Kir2.1 channels with synapse-associated protein 97 (SAP97), calmodulin-dependent serine protein kinase (CASK), Veli, and Mint1 and their contribution to protein trafficking was shown (Leonoudakis et al., 2004).

  3. Kir4.1 in glial cells and Kir2.2 in muscle were shown to associate with the dystrophin-glycoprotein complex via α-syntrophin (Connors et al., 2004).

  4. Kir4.1 has been associated with epilepsy in both causative and protective roles (Buono et al., 2004; Ferraro et al., 2004; Leonoudakis et al., 2004).

  5. It was shown that the loss of Kir 4.1 expression abolishes endocochlear potential and causes deafness in Pendred syndrome (Wangemann et al., 2004).

  6. The disruption of Kir6.1 gene in mice was reported to cause phenotypes similar to those of vasospastic (Prinzmetal) angina (Miki et al., 2002).

  7. It was shown that an activating mutation of Kir6.2 causes permanent neonatal diabetes (Gloyn et al., 2004).

Although it is not discussed herein, among the most exciting recent developments are those involving X-ray crystal structure analysis, including studies describing the structure of the cytoplasmic region of Kir3.1 (Nishida and MacKinnon, 2002), the entire structure of the bacterial Kir1.1 channel (Kuo et al., 2003), and the cytoplasmic region of Kir2.1 (Pegan et al., 2005). These studies demonstrated that inward rectifier K+ channels have a long cytoplasmic pore and confirmed the significance of negatively charged amino acids on the wall of the cytoplasmic pore that have been known to play critical roles for inward rectification. They also provided structure-based clues for the regulation mechanisms of gating by ligands such as G proteins and phosphatidylinositol 4,5-bisphosphate. The information yielded by analysis of crystal structures is extremely valuable since it will enable more precise approaches to establishing structure-function relationships. Also noteworthy are published studies on the dynamic aspects of channel function using fluorescence resonance energy transfer analysis of fluorescent-labeled molecules (Riven et al., 2003). Knowledge of these dynamic aspects of Kir channel function may also be expected to expand in the near future.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Phylogenetic tree of Kir channels. Amino acid sequence alignments and phylogenetic analysis for the 15 known members of the human Kir family were generated as described in the legend for Fig. 1 of “LIII. Nomenclature and Molecular Relationships of Voltage-Gated Potassiuim Channels”. No new channels have been added to this topology since it appeared in the earlier edition of this compendium. International Union of Pharmacology and HUGO Gene Nomenclature Committee names of the genes are shown together with their chromosomal localization.

A great deal of additional knowledge on Kir function, structure-function relationships, regulation of expression, and links with diseases has been accumulated. Since it is not possible to describe it in detail here, we refer the reader instead to several excellent recent reviews (Stanfield et al., 2002; Bichet et al., 2003; Lu, 2004). See Tables 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 for Kir1 through Kir7.1.

View this table:
  • View inline
  • View popup
TABLE 1

Kir1.1 channels

View this table:
  • View inline
  • View popup
TABLE 2

Kir2.1 channels

View this table:
  • View inline
  • View popup
TABLE 3

Kir2.2 channels

View this table:
  • View inline
  • View popup
TABLE 4

Kir2.3 channels

View this table:
  • View inline
  • View popup
TABLE 5

Kir2.4 channels

View this table:
  • View inline
  • View popup
TABLE 6

Kir3.1 channels

View this table:
  • View inline
  • View popup
TABLE 7

Kir3.2 channels

View this table:
  • View inline
  • View popup
TABLE 8

Kir3.3 channels

View this table:
  • View inline
  • View popup
TABLE 9

Kir3.4 channels

View this table:
  • View inline
  • View popup
TABLE 10

Kir4.1 channels

View this table:
  • View inline
  • View popup
TABLE 11

Kir4.2 channels

View this table:
  • View inline
  • View popup
TABLE 12

Kir5.1 channels

View this table:
  • View inline
  • View popup
TABLE 13

Kir6.1 channels

View this table:
  • View inline
  • View popup
TABLE 14

Kir6.2 channels

View this table:
  • View inline
  • View popup
TABLE 15

Kir7.1 channels

Acknowledgments

We gratefully acknowledge the support of Drs. Atsushi Inanobe (Kurachi Lab), Wade Pearson (Nichols Lab), and Florian Lesage (Lazdunski Lab) and the contributions of Dr. Henry Lester (California Institute of Technology, Pasadena, CA) to the earlier edition of this compendium.

Footnotes

  • The authors serve as the Subcommittee on Kir channels of the Nomenclature Committee of the International Union of Pharmacology.

  • Article, publication date, and citation information can be found at http://pharmrev.aspetjournals.org.

  • doi:10.1124/pr.57.4.11.

  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    Bichet D, Haass FA, and Jan LY (2003) Merging functional studies with structures of inward rectifier K+ channels. Nat Rev Neurosci 4: 957-967.
    OpenUrlCrossRefPubMed
  2. ↵
    Buono RJ, Lohoff FW, Sander T, Sperling MR, O'Connor MJ, Dlugos DJ, Ryan SG, den GT, Zhao H, Scattergood TM, et al. (2004) Association between variation in the human KCNJ10 potassium ion channel gene and seizure susceptibility. Epilepsy Res 58: 175-183.
    OpenUrlCrossRefPubMed
  3. ↵
    Connors NC, Adams ME, Froehner SC, and Kofuji P (2004) The potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex via alpha-syntrophin in glia. J Biol Chem 279: 28387-28392.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Ferraro TN, Golden GT, Smith GG, Martin JF, Lohoff FW, Gieringer TA, Zamboni D, Schwebel CL, Press DM, Kratzer SO, et al. (2004) Fine mapping of a seizure susceptibility locus on mouse chromosome 1: nomination of Kcnj10 as a causative gene. Mamm Genome 15: 239-251.
    OpenUrlCrossRefPubMed
  5. ↵
    Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, et al. (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350: 1838-1849; erratum in N Engl J Med 351:1470.
    OpenUrlCrossRefPubMed
  6. ↵
    Kubo Y, Adelman JP, Clapham DE, Jan LY, Karschin A, Kurachi Y, Lazdunski M, Lester HA, Nichols CG, et al. (2002) Kir potassium channels, in The IUPHAR Compendium of Voltage-gated Ion Channels (Catterall WA, Chandy KG, and Gutman G eds) pp 153-172, IUPHAR Media, Leeds, UK.
  7. ↵
    Kuo A, Gulbis JM, Antcliff JF, Rahman T, Lowe ED, Zimmer J, Cuthbertson J, Ashcroft FM, Ezaki T, and Doyle DA (2003) Crystal structure of the potassium channel KirBac1.1 in the closed state. Science (Wash DC) 300: 1922-1926.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Leonoudakis D, Conti LR, Anderson S, Radeke CM, McGuire LMM, Adams ME, Froehner SC, Yates JR 3rd, and Vandenberg CA (2004) Protein trafficking and anchoring complexes revealed by proteomic analysis of inward rectifier potassium channel (Kir2x)-associated proteins. J Biol Chem 279: 22331-22346.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Lu Z (2004) Mechanism of rectification in inward rectifier K+ channels. Annu Rev Physiol 66: 103-129.
    OpenUrlCrossRefPubMed
  10. ↵
    Miki T, Suzuki M, Shibasaki T, Uemura H, Sato T, Yamaguchi K, Koseki H, Iwanaga T, Nakaya H, and Seino S (2002) Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat Med 8: 466-472.
    OpenUrlCrossRefPubMed
  11. ↵
    Nishida M and MacKinnon R (2002) Structural basis of inward rectification: cytoplasmic pore of the G-protein-gated inward rectifier GIRK1 at 1.8 A resolution. Cell 111: 957-965.
    OpenUrlCrossRefPubMed
  12. ↵
    Pegan S, Arrabit C, Zhou W, Kwiatkowski W, Collins A, Slesinger PA, and Choe S (2005) Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification. Nat Neurosci 8: 279-287.
    OpenUrlCrossRefPubMed
  13. ↵
    Riven I, Kalmanzon E, Segev L, and Reuveny E (2003) Conformational rearrangements associated with the gating of the G protein-coupled potassium channel revealed by FRET microscopy. Neuron 38: 225-235.
    OpenUrlCrossRefPubMed
  14. ↵
    Stanfield PR, Nakajima S, and Nakajima Y (2002) Constitutively active and G-protein coupled inward rectifier K+ channels: Kir2.0 and Kir3.0. Rev Physiol Biochem Pharmacol 145: 47-179.
    OpenUrlCrossRefPubMed
  15. ↵
    Yoo D, Flagg TP, Olsen O, Raghuram V, Foskett JK, and Welling PA (2004) Assembly and trafficking of a multiprotein ROMK (Kir 1.1) channel complex by PDZ interactions. J Biol Chem 279: 6863-6873.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Wangemann P, Itza EM, Albrecht B, Wu T, Jabba SV, Maganti RJ, Lee JH, Everett LA, Wall SM, Royaux IE, et al. (2004) Loss of KCNJ10 protein expression abolishes endocochlear potential and causes deafness in Pendred syndrome mouse model. BMC Med 2: 30.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Pharmacological Reviews: 57 (4)
Pharmacological Reviews
Vol. 57, Issue 4
1 Dec 2005
  • Table of Contents
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
International Union of Pharmacology. LIV. Nomenclature and Molecular Relationships of Inwardly Rectifying Potassium Channels
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherIUPHAR Compendium of Voltage-Gated Ion Channels 2005

International Union of Pharmacology. LIV. Nomenclature and Molecular Relationships of Inwardly Rectifying Potassium Channels

Yoshihiro Kubo, John P. Adelman, David E. Clapham, Lily Y. Jan, Andreas Karschin, Yoshihisa Kurachi, Michel Lazdunski, Colin G. Nichols, Susumu Seino and Carol A. Vandenberg
Pharmacological Reviews December 1, 2005, 57 (4) 509-526; DOI: https://doi.org/10.1124/pr.57.4.11

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherIUPHAR Compendium of Voltage-Gated Ion Channels 2005

International Union of Pharmacology. LIV. Nomenclature and Molecular Relationships of Inwardly Rectifying Potassium Channels

Yoshihiro Kubo, John P. Adelman, David E. Clapham, Lily Y. Jan, Andreas Karschin, Yoshihisa Kurachi, Michel Lazdunski, Colin G. Nichols, Susumu Seino and Carol A. Vandenberg
Pharmacological Reviews December 1, 2005, 57 (4) 509-526; DOI: https://doi.org/10.1124/pr.57.4.11
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • International Union of Pharmacology. XLIX. Nomenclature and Structure-Function Relationships of Transient Receptor Potential Channels
  • International Union of Pharmacology. L. Nomenclature and Structure-Function Relationships of CatSper and Two-Pore Channels
  • International Union of Pharmacology. LI. Nomenclature and Structure-Function Relationships of Cyclic Nucleotide-Regulated Channels
Show more IUPHAR Compendium of Voltage-Gated Ion Channels 2005

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics